Cargando…
Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19
Autores principales: | Gao, Yuan, Luo, Zujin, Ren, Shan, Duan, Zhonghui, Han, Ying, Liu, Huihang, Gao, Ziwen, Zhang, Xinyu, Hu, Zhongjie, Ma, Yingmin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10062713/ https://www.ncbi.nlm.nih.gov/pubmed/37003523 http://dx.doi.org/10.1016/j.jinf.2023.03.023 |
Ejemplares similares
-
Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study
por: Zhao, Xiang, et al.
Publicado: (2023) -
Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study
por: Zhao, Qinqin, et al.
Publicado: (2023) -
COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy
por: Coulson, J.M., et al.
Publicado: (2022) -
Nirmatrelvir/ritonavir as a possible treatment for Long-COVID
por: Catalán, Ignacio Pérez, et al.
Publicado: (2023) -
Post-acute hospitalization and mortality of nirmatrelvir plus ritonavir for COVID-19 survivors
por: Hsu, Wan-Hsuan, et al.
Publicado: (2023)